

Vaccine Virtual Days

Vaccination during COVID-19:
Extraordinary challenges call for
extraordinary connections

29–30 June,
2020



Agenda

Programme at-a-glance


Please **click on the session title** for more details.

A full listing of the Vaccine Virtual Days speakers can also be viewed [here](#).

Please note that depending on your country regulations you may not be able to participate in each session.

Day 1, 29 June, 13:00–21:00 CEST (GMT+2 Belgium)		
	Session	Topics include:
13:15–16:20	<u>Life course immunization</u>	<ul style="list-style-type: none"> Innovative methods for vaccination delivery Rationale for National Immunizations Technical Advisory Groups recommendations, ways of working Maternal immunization Vaccination of older adults Vaccination of special populations
16:35–18:15	<u>Nonspecific vaccine effects</u>	<ul style="list-style-type: none"> Trained immunity: a memory for innate host defense BCG: From ecological studies to evidence from clinical trials. Is there reliable data showing any impact of BCG on COVID-19? Impact of early measles vaccination on mortality and the role of memory B cells Impact of influenza vaccines in respiratory infections
18:30–21:00	<u>Assessing vaccine safety and confidence in the COVID-19 era. What needs to be done?</u>	<ul style="list-style-type: none"> Vaccine confidence in the age of coronavirus including impact of COVID-19 on vaccination programs The HPV vaccines and vaccine confidence; what went wrong? How can this approach inform the COVID-19 vaccination? Will America accept a COVID-19 vaccine? Enhanced disease: How to assess it and how to minimize risk? Considerations for COVID-19 vaccines development. Vaccine assessment after vaccine introduction: How to keep the public informed? Challenges associated with COVID-19 vaccine development and implementation
Day 2, 30 June, 14:00–22:15 CEST (GMT+2 Belgium)		
14:00–16:15	<u>Respiratory pathogens: focus on SARS-CoV-2/COVID-19</u>	<ul style="list-style-type: none"> Immune response to SARS-CoV-2 infection: how does it compare to other respiratory pathogens? Pathogenesis of COVID-19: is it something unique? Clinical features of COVID-19: from asymptomatic infection to deadly disease New therapeutic strategies for COVID-19: what are the challenges? The known unknown and the unknown known
16:30–19:10	<u>Vaccine development</u>	<ul style="list-style-type: none"> Overview of general vaccine development Traditional technology platforms Newer technology platforms Emerging technology platforms
19:25–22:15	<u>Antimicrobial resistance</u>	<ul style="list-style-type: none"> Outline of the AMR problem Antibiotics and evolution The role and advantages of vaccines in reducing AMR Role of biological standards in reducing AMR The economic value of vaccination Vaccine pipelines
On-demand scientific videos		
From 08:00 CEST (GMT+2) on 29 June	Click here to discover the range of topics covered 'on demand'	

Sessions labelled with the following icons may be of interest to:

	Paediatricians
	General practitioners
	Obstetricians and gynaecologists
	Infectious disease specialists
	Vaccinators
	Vaccine developers
	Public health experts
	Immunologists
	Pulmonologists

Day 1, 29 June
13:00–16:20 CEST (GMT+2 Belgium)

Session: Life course immunization			
Moderators: Markus Knuf and Paolo Bonanni			
13:00–13:15		Opening by Peter Piot	
Life course immunization: Part 1			   
	Topic	Description	Speakers
13:15–13:25	Life course immunization	Introduction	Paolo Bonanni (Italy) Markus Knuf (Germany)
13:25–13:50	Innovative methods for vaccinations delivery	Best practice sharing: <ul style="list-style-type: none"> • Mobile unit for paediatric vaccination • Drive-through clinics • Communication campaign around vaccination during pandemic Discussion + Q&A	Chair: Markus Knuf (Germany) Speakers: Mona Doss (USA) Rod Pearce (Australia) Hiền Minh Nguyễn (Vietnam)
13:50–13:55 Topic break			
13:55–14:25	Rationale for NITAG recommendations, ways of working	Round table discussion <ul style="list-style-type: none"> • Decision making process of recommendation bodies: Different countries – different decisions 	Chair: Paolo Bonanni (Italy) Speakers: Paolo Bonanni (Italy) TBC
14:25–14:40 Sub-session break			
Life course immunization: Part 2			     
14:40–15:10	Maternal immunization	Round table discussion: Current concepts and future directions Discussion + Q&A	Chairs: Paolo Bonanni (Italy) and Markus Knuf (Germany) Speakers: Flor Muñoz-Rivas (USA) Elke Leuridan (Belgium)
15:10–15:15 Topic break			
15:15–15:45	Vaccination of older adults	Benefit of vaccination for older adults Older adults, how to reach? Discussion + Q&A	Chair: Paolo Bonanni (Italy) Speakers: Jean-Pierre Michel (Switzerland) Stefania Maggi (Italy)
15:45–15:50 Topic break			
15:50–16:20	Vaccination of special populations	Vaccination of preterm Vaccination of immunocompromised Discussion + Q&A	Chair: Paolo Bonanni (Italy) Speakers: Markus Knuf (Germany) Susanna Esposito (Italy)
16:20–16:35 Session break			

Day 1, 29 June
16:35–18:15 CEST (GMT+2 Belgium)

Session: Nonspecific vaccine effects			
Moderator: Marco Sáfadi			
	Topic	Description	Speakers
16:35–16:45	Nonspecific effects of vaccines	Introduction	Marco Sáfadi (Brazil)
16:45–17:00	Trained immunity: a memory for innate host defense	Presentation	Mihai Netea (Netherlands)
17:00–17:15	BCG: From ecological studies to evidence from clinical trials. Is there reliable data showing any impact of BCG on COVID-19 risk?	Presentation	TBC
17:15–17:30	“Magic” effects of measles vaccine on immune memory	Presentation	Federico Martinón Torres (Spain)
17:30–17:45	Impact of influenza vaccination on other respiratory virus infections	Presentation	Albert Osterhaus (Germany)
17:45–18:15	Discussion	Q&A	Moderator: Marco Sáfadi (Brazil) Speakers: Mihai Netea (Netherlands) Federico Martinón Torres (Spain) Albert Osterhaus (Germany)
18:15–18:30	Session break		

Day 1, 29 June
18:30–20:15 CEST (GMT+2 Belgium)

Session: Assessing vaccine safety and confidence in the COVID-19 era.
What needs to be done?

Moderator: Steve Black

	Topic	Description	Speakers
18:30–18:35	Vaccine safety and confidence	Introduction	Steve Black (USA)
Vaccine safety and confidence: Part 1			
18:35–18:50	Vaccine confidence in the age of coronavirus including impact of COVID-19 on vaccination programs	Presentation	Heidi Larson (UK)
18:50–19:05	HPV vaccines and vaccine confidence: what went wrong? How can this approach inform the COVID-19 vaccination?	Presentation	Margaret Stanley (UK)
19:05–19:15	Discussion	Q&A	Moderator: Steve Black (USA) Speakers: Heidi Larson (UK) Margaret Stanley (UK)
19:15–19:20	Topic break		
19:20–19:35	Will America accept a COVID-19 vaccine?	Presentation	TBC
19:35–19:50	Enhanced disease: How to assess it and how to minimize risk? Considerations for COVID-19 vaccines development.	Presentation	Paul-Henri Lambert (Switzerland)
19:50–20:05	Vaccine assessment after vaccine introduction. How to keep the public informed?	Presentation	Miriam Sturkenboom (Netherlands)
20:05–20:15	Discussion	Q&A	Moderator: David Salisbury (UK) Speakers: TBC Paul-Henri Lambert (Switzerland) Miriam Sturkenboom (Netherlands)
20:15–20:30	Sub-session break		

Day 1, 29 June
20:30–21:00 CEST (GMT+2 Belgium)

Vaccine safety and confidence: Part 2			
	Topic	Description	Speakers
20:30–21:00	Challenges associated with COVID-19 vaccine development and implementation	Round table	Moderator: David Salisbury (UK) Speakers: Heidi Larson (UK) Margaret Stanley (UK) TBC Paul-Henri Lambert (Switzerland) Thomas Breuer (GSK - Belgium)

Day 2, 30 June
14:00–15:00 CEST (GMT+2 Belgium)

14:00–14:15

Opening by Peter Piot

Session: Respiratory pathogens - focus on SARS-CoV-2/COVID-19

Moderator: Philippe Buchy







	Topic	Description	Speakers
14:15–14:30	Immune response to SARS-CoV-2 infection: how does it compare to other respiratory pathogens?	Presentation	Malik Peiris (Hong Kong)
14:30–14:35	Discussion	Q&A	Malik Peiris (Hong Kong)
14:35–14:50	Pathogenesis of COVID-19: is it something unique?	Presentation	Malik Peiris (Hong Kong)
14:50–14:55	Discussion	Q&A	Malik Peiris (Hong Kong)
14:55–15:00	Topic break		





Day 2, 30 June
15:00–16:15 CEST (GMT+2 Belgium)

	Topic	Description	Speakers
15:00–15:15	Clinical features of COVID-19: from asymptomatic infection to deadly disease	Presentation	TBC
15:15–15:20	Discussion	Q&A	TBC
15:20–15:35	New therapeutic strategies for COVID-19: what are the challenges?	Presentation	TBC
15:35–15:40	Discussion	Q&A	TBC
15:40–15:45	Topic break		
15:45–16:15	The known unknown and the unknown known	Round table	Moderator: Philippe Buchy (GSK - SG) Speakers: Malik Peiris (Hong Kong) TBC
16:15–16:30	Session break		

Day 2, 30 June
16:30–17:45 CEST (GMT+2 Belgium)

Session: Vaccine development			
Moderators: Stanley Plotkin and Albert Osterhaus			
	Topic	Description	Speakers
16:30–16:35	Vaccine development	Introduction	Stanley Plotkin (USA) Albert Osterhaus (Germany)
Vaccine development: Part 1			   
16:35–16:55	Overview general vaccine development	<ul style="list-style-type: none"> • Preclinical/clinical/post marketing • Regulatory considerations in evaluating vaccine safety and efficacy 	Bart Haagmans (Netherlands) Philip Krause (USA)
16:55–17:05	Discussion	Q&A	Moderator: Stanley Plotkin (USA) Speakers: Bart Haagmans (Netherlands) Philip Krause (USA)
17:05–17:35	Traditional technology platforms	<ul style="list-style-type: none"> • Live attenuated, inactivated • Polysaccharide conjugate • Subunits – recombinant proteins and virus-like particles (VLPs) 	Stanley Plotkin (USA) George Siber (USA) Berend-Jan Bosch (Netherlands)
17:35–17:45	Discussion	Q&A	Moderator: Albert Osterhaus (Germany) Speakers: George Siber (USA) Berend-Jan Bosch (Netherlands)
17:45–18:00	Sub-session break		



Day 2, 30 June
18:00–19:10 CEST (GMT+2 Belgium)

Vaccine development: Part 2    			
	Topic	Description	Speakers
18:00–18:20	Newer technology platforms	<ul style="list-style-type: none"> Reverse vaccinology/ structural vaccinology Adjuvants 	Rino Rappuoli (GSK - Italy) Thomas Breuer (GSK - Belgium)
18:20–18:30	Discussion	Q&A	Moderator: Albert Osterhaus (Germany) Speakers: Rino Rappuoli (GSK - Italy) Thomas Breuer (GSK - Belgium)
18:30–19:00	Emerging technology platforms	<ul style="list-style-type: none"> Nucleic acid – RNA Nucleic acid – DNA Vectors 	Drew Weisman (USA) TBC TBC
19:00–19:10	Discussion	Q&A	Moderator: Stanley Plotkin (USA) Speakers: Drew Weisman (USA) TBC
19:10–19:25	Session break		

Day 2, 30 June
19:25–22:15 CEST (GMT+2 Belgium)

Session: Antimicrobial resistance

Moderator: Ian Feavers

	Topic	Description	Speakers
19:25–19:30	Antimicrobial resistance	Introduction	Ian Feavers (UK)
Antimicrobial resistance: Part 1			
19:30–19:45	Outline of the AMR problem	Presentation and Q&A	Jim O'Neill (UK)
19:45–20:00	Antibiotics and evolution	Presentation and Q&A	Gordon Dougan (UK)
20:00–20:15	The role and advantages of vaccines in reducing AMR	Presentation and Q&A	Mariagrazia Pizza (GSK - Italy)
20:15–20:30	Role of biological standards in reducing AMR	Presentation and Q&A	Ian Feavers (UK)
20:30–20:45	The economic value of vaccination	Presentation and Q&A	TBC
20:45–21:15	Sub-session break		
Antimicrobial resistance: Part 2			
21:15–22:15	Vaccine pipelines	Presentation and Q&A <ul style="list-style-type: none"> • Progress on Bacterial Enteric Vaccines • Progress on gonococcal vaccines • Progress on TB vaccines • Progress on malaria vaccines 	Calman MacLennan (UK) Kate Seib (Australia) TBC Ashly Birkett (USA)

On-demand scientific videos

Available from 08:00 CEST (GMT+2 Belgium) on 29 June, 2020

Continuous session: On-demand scientific videos

Topic	Description	Format
General immune response to infection	This short animation recaps how our innate and adaptive immune systems each respond to a pathogen invasion	Video (approx. 2 min)
Vaccine safety evaluation: practical aspects in assessing benefits and risks	Vaccines are different from most medicines in that they are administered to large and mostly healthy populations, including infants and children, so there is a low tolerance for potential risks or side-effects. The breadth and depth of safety assessments conducted at multiple levels by a range of independent organizations increases confidence in the rigour with which any potential risks or side-effects are investigated and managed. You will watch here a short video addressing how all parties ensure that licensed vaccines have a favourable benefit–risk profile	Video (approx. 4 min)
“I’ve had that vaccine already – why would I need it again?”	A simple recap of the reasons why booster vaccinations are necessary	Video (approx. 90 sec)
An introduction to vaccine adjuvants	Get a first introduction to key concepts related to vaccine adjuvants	Video (approx. 90 sec)
Understanding adjuvant mode of action in vaccines	Interested in gaining a good understanding about the mode of action of vaccine adjuvants? This video animation will provide you with the key elements that you will need	Video (approx. 6 min)
Assessing the safety of adjuvants	This video reviews the most important aspects of safety related to vaccines adjuvants, from discovery throughout adjuvanted vaccine development and post-licensure	Video (approx. 4 min)
Maternal immunization	Interested in gaining a better understanding of what is so-called “maternal immunization”? This animation will highlight for you some of its main elements in simple terms, from its rationale to its benefit, highlighting safety and other important aspects	Animation (approx. 6 min)
Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion	As the global population ages, there is concern about the effect of an increased proportion of older individuals on the economic sustainability of healthcare systems. Strategies are now developed to ameliorate the social and financial effects of an ageing population. There is broad agreement that, for both society and for the individuals, it is important to ensure that increasing lifespans are matched with increased “healthspans” – the number of years spent in good health. There is also growing consensus that vaccination is one of the tools that can play an important role in improving adult health	Video (approx. 2 min)
Vaccination of healthcare personnel	Attend this presentation by a GSK expert to familiarize yourself with some of the key aspects and challenges of healthcare personnel immunization	Video (approx. 11 min)

Topic	Description	Format
Vaccine confidence	This presentation by a GSK expert reviews the most important aspects of vaccine confidence, including public hesitancy and provides some useful tips about how to communicate with individuals who are hesitant about vaccination	Video (approx. 28 min)
Towards a more comprehensive approach for a total health economic assessment of vaccines? The building blocks for a health economic assessment	Because a vaccination programme is an economic social choice, how should it be valued? To date, the economic evaluations developed for treatments have been applied to vaccines. However, over 25 different characteristics differentiate vaccines from drug treatments. For example, the benefit of vaccination is measured at the population level not at the individual level; the main effect of prevention is societal and not an individual-based gain only, and the biggest hurdle to implement a new vaccine is the initial budget investment and not so much its estimated 'value for money'. This makes the current application of incremental cost-utility analysis difficult for vaccines for a comprehensive evaluation. New approaches may be needed to capture the full economic benefit of vaccines	Video (approx. 4 min)

Vaccine Virtual Days speakers (alphabetical order)

Scientific Committee		
Name	Affiliation(s)	Country of residence
Albert Osterhaus	Scientific Head, Research Center for Emerging Infections and Zoonoses, TiHo Hannover (RIZ-TiHo)	Germany
Ian Feavers	Senior Research Associate, University of Oxford and Head of Bacteriology at the National Institute for Biological Standards	UK
Malik Peiris	Chair Professor of Microbiology and Tam Wah-Ching Professor of Medical Sciences at The University of Hong Kong, Honorary Consultant Microbiologist at Queen Mary Hospital and the Scientific Director of the HKU-Pasteur Research Centre	Hong Kong
Marco Sáfadi	Head of the Department of Pediatrics, Santa Casa de São Paulo School of Medicine, São Paulo	Brazil
Markus Knuf	Medical Director of the Children's Hospital at Helios Dr Horst Schmidt Kliniken Wiesbaden, and Academic Head, Paediatric Infectious Diseases at Johannes Gutenberg-Universität Mainz, Mainz	Germany
Paolo Bonanni	Professor of Hygiene in the Faculty of Medicine, University of Florence	Italy
Stanley Plotkin	Emeritus Professor of Pediatrics at the University of Pennsylvania, Emeritus Professor of the Wistar Institute, and Adjunct Professor of International Health at Johns Hopkins University, Baltimore, MD	USA
Steven Black	Emeritus Professor of Pediatrics in the Division of Infectious Diseases at the Cincinnati Children's Hospital, Cincinnati, and Associate Clinical Professor in the Department of Pediatrics at the University of California, San Francisco, CA	USA
Speakers		
Name	Affiliation(s)	Country of residence
Ashley Birkett	Director of PATH's Malaria Vaccine Initiative (MVI), Washington, DC	USA
Bart Haagmans	Principal Investigator, Department of Virology, Erasmus MC	Netherlands
Berend Jan Bosch	Associate Professor, Virology Division, Department of Infectious Diseases & Immunology, Faculty of Veterinary Medicine, Utrecht University	Netherlands
Calman MacLennan	Professor of Vaccine Immunology at the Jenner Institute, University of Oxford, and Group Head/Principal Investigator, Consultant Physician and Fellow of the Nuffield Department of Medicine, University of Oxford	UK
David Salisbury	Chair of the Global Certification Commission, Chair of the European Certification Commission, member of the Eastern Mediterranean Commission and member of the South East Asian Commission on Poliomyelitis Eradication	UK
Drew Weisman	Professor of Medicine and Graduate Group Affiliations in Immunology & Cell and Molecular Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA	USA
Elke Leuridan	General Practitioner and Researcher at University of Antwerp	Belgium
Federico Martín Torres	Associate Professor, Coordinator of Genetics, Vaccines, Infections and Pediatrics Research Group (GENVIP)	Spain

Vaccine Virtual Days Agenda



Name	Affiliation(s)	Country of residence
Flor Muñoz-Rivas	Associate Professor of Pediatrics and Infectious Diseases at Texas Children's Hospital and Baylor College of Medicine in Houston, TX	USA
George Siber	Adjunct Professor of Medicine at Johns Hopkins Medical School, Baltimore, MD, and Chief Scientific Officer at ClearPath Vaccines	USA
Gordon Dougan	Professor, Department of Medicine, Cambridge University, Cambridge	UK
Heidi Larson	Director of The Vaccine Confidence Project; Professor of Anthropology, Risk and Decision Science, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine; Associate Professor, Department of Global Health, University of Washington; and Chatham House Centre on Global Health Security Fellow	UK
Hiền Minh Nguyễn	Deputy Medical Director at VNVC Vietnam Vaccine JSC and Medical Advisor at ECO Pharma JSC, Ho Chi Minh City	Vietnam
Jean-Pierre Michel	Department of Rehabilitation and Geriatrics, University of Geneva	Switzerland
Jim O'Neill	Chair of Chatham House, Royal Institute of International Affairs, London	UK
Kate Seib	Principal Research Fellow/Associate Professor and Associate Director (Research) at the Institute for Glycomics, Griffith University	Australia
Margaret Stanley	Emeritus Professor of Epithelial Biology at the University of Cambridge, Cambridge	UK
Mariagrazia Pizza	Senior Scientific Director Bacterial Vaccines R&D, GSK Vaccines	Italy
Mihai Netea	Head, Division of Experimental Medicine, Department of Internal Medicine, Nijmegen University Nijmegen Medical Center	Netherlands
Miriam Sturkenboom	Pharmacoepidemiologist and Professor in Observational Data Analysis at the Julius Global Health Group of University Medical Center Utrecht, Utrecht	The Netherlands
Mona Doss	Assistant Professor of Medicine at Boston University School of Medicine and Pediatrician at the Boston Medical Center, Boston, MA	USA
Paul-Henri Lambert	Emeritus Professor at the Centre of Vaccinology in the Department of Pathology and Immunology at the University of Geneva, and Director of the International Advanced Course of Vaccinology, University of Geneva, Geneva	Switzerland
Peter Piot	Director of the School and a Handa Professor of Global Health	UK
Philip Krause	Assistant Professor of Medicine, Rush Medical College and Senior Clinical Educator, University of Chicago/Pritzker School of Medicine, Chicago, IL, "Deputy Director of FDA's Office of Vaccines Research and Review	USA
Philippe Buchy	Director, Scientific Affairs & Public Health Greater China & Intercontinental Vaccines Medical, GSK Vaccines	Singapore
Rino Rappuoli	GSK Chief Scientist and Head of External R&D	Italy
Rodney Pearce	General Practitioner in Glynde, South Australia, and Chairman of the Board of Directors of the Immunisation Coalition	Australia
Stefania Maggi	Senior Researcher, National Research Council of Italy, Aging Section-Institute of Neuroscience	Italy
Susanna Esposito	Director of Pediatric Clinic, Pietro Barilla Children's Hospital, Parma, and World Association for Infectious Diseases and Immunological Disorders (WAidid) President	Italy
Thomas Breuer	Senior Vice President, Chief Medical Officer, GSK Vaccines	Belgium



Please report adverse events to the Belgian Centre for Pharmacovigilance for medicines for Human use of the Federal Agency for Medicines and Health Products adversedrugreactions@afmps.be or via the 'yellow card' available on www.fagg-afmps.be or to GlaxoSmithKline Pharmaceuticals s.a./n.v. 010/ 85 85 00.

For other countries, to report adverse events, details can be found at: <https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/>

GlaxoSmithKline Biologicals SA. Rixensart, Belgium
<https://be.gsk.com/en/>
© 2020 GSK group of companies or its licensor. All rights reserved.
June 2020 | SE-GBL-GVX-AGND-200001